FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells

Jiang,Chengfei; Yuan,Binbin; Hang,Bo; Mao,Jian-Hua; Zou,Xiaoping; Wang,Pin

doi:10.3892/ol.2021.12973

FHOD1 is upregulated in gastric cancer and promotes the proliferation and invasion of gastric cancer cells

Authors:
- Chengfei Jiang
- Binbin Yuan
- Bo Hang
- Jian-Hua Mao
- Xiaoping Zou
- Pin Wang
View Affiliations

Affiliations: Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008, P.R. China, Biological Systems and Engineering Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
Published online on: August 5, 2021 https://doi.org/10.3892/ol.2021.12973
Article Number: 712

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the main causes of cancer‑associated morbidity and mortality worldwide. The present study aimed to investigate the role of the gene encoding formin homology 2 domain containing 1 (FHOD1) protein in GC development. Data from The Cancer Genome Atlas were firstly analyzed, and immunohistochemistry was conducted on GC tissues. The results demonstrated that FHOD1 expression in GC tissues was significantly increased compared with adjacent non‑tumor tissues. Furthermore, the expression level of FHOD1 was negatively associated with the overall survival of patients with GC. For the functional studies, lentivirus‑mediated short hairpin RNA against FHOD1 and FHOD1‑overexpression vectors were constructed to knockdown and overexpress the expression level of FHOD1 in human GC cell lines, respectively. The results indicated that FHOD1 knockdown inhibited the proliferation, colony formation and migratory and invasive abilities of GC cells. Conversely, overexpression of FHOD1 in GC cells promoted soft‑agar colony formation and migratory and invasive abilities. In addition, it was demonstrated that genes of which expression levels were correlated with FHOD1 were enriched in the Gene Ontology term of ‘extracellular matrix (ECM) structural constituent', suggesting that FHOD1 may serve an important role in the regulation of ECM. In conclusion, the present study demonstrated that FHOD1 may exert an oncogenic role in cultured GC cells and be inversely associated with the overall survival of patients with GC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Global Burden of Disease Cancer Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015. View Article : Google Scholar : PubMed/NCBI
3	International Agency for Research on Cancer (IARC), . Cancer Fact Sheets, Digestive organs. IARC; Lyon: 2020, https://gco.iarc.fr/today/fact-sheets-cancerDecember. 2020
4	National Cancer Institute (NIH), . Cancer Stat Facts: Stomach cancer. NIH; Bethesda, MD: 2021, https://seer.cancer.gov/statfacts/html/stomach.html
5	Bevan S and Houlston RS: Genetic predisposition to gastric cancer. QJM. 92:5–10. 1999. View Article : Google Scholar : PubMed/NCBI
6	Ushijima T and Sasako M: Focus on gastric cancer. Cancer Cell. 5:121–125. 2004. View Article : Google Scholar : PubMed/NCBI
7	Wang P, Wang Y, Hang B, Zou X and Mao JH: A novel gene expression-based prognostic scoring system to predict survival in gastric cancer. Oncotarget. 7:55343–55351. 2016. View Article : Google Scholar : PubMed/NCBI
8	Cui J, Li F, Wang G, Fang X, Puett JD and Xu Y: Gene-expression signatures can distinguish gastric cancer grades and stages. PLoS One. 6:e178192011. View Article : Google Scholar : PubMed/NCBI
9	Mattioni M, Soddu S, Porrello A, D'Alessandro R, Spila A and Guadagni F: Serum anti-p53 antibodies as a useful marker for prognosis of gastric carcinoma. Int J Biol Markers. 22:302–306. 2007. View Article : Google Scholar : PubMed/NCBI
10	Takeno A, Takemasa I, Doki Y, Yamasaki M, Miyata H, Takiguchi S, Fujiwara Y, Matsubara K and Monden M: Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br J Cancer. 99:1307–1315. 2008. View Article : Google Scholar : PubMed/NCBI
11	Heuser VD, Kiviniemi A, Lehtinen L, Munthe S, Kristensen BW, Posti JP, Sipilä JOT, Vuorinen V, Carpén O and Gardberg M: Multiple formin proteins participate in glioblastoma migration. BMC Cancer. 20:7102020. View Article : Google Scholar : PubMed/NCBI
12	Zhao S, Cai J, Zhang X, Cui J and Jiu Y: Different formins restrict localization of distinct tropomyosins on dorsal stress fibers in osteosarcoma cells. Cytoskeleton (Hoboken). 77:16–24. 2020. View Article : Google Scholar : PubMed/NCBI
13	Alvarez DE and Agaisse H: A role for the small GTPase Rac1 in vaccinia actin-based motility. Small GTPases. 6:119–122. 2015. View Article : Google Scholar : PubMed/NCBI
14	Schulte A, Stolp B, Schönichen A, Pylypenko O, Rak A, Fackler OT and Geyer M: The human formin FHOD1 contains a bipartite structure of FH3 and GTPase-binding domains required for activation. Structure. 16:1313–1323. 2008. View Article : Google Scholar : PubMed/NCBI
15	Heuser VD, Mansuri N, Mogg J, Kurki S, Repo H, Kronqvist P, Carpén O and Gardberg M: Formin proteins FHOD1 and INF2 in triple-negative breast cancer: Association with basal markers and functional activities. Breast Cancer (Auckl). 12:11782234187922472018.PubMed/NCBI
16	Sun BO, Fang Y, Li Z, Chen Z and Xiang J: Role of cellular cytoskeleton in epithelial-mesenchymal transition process during cancer progression. Biomed Rep. 3:603–610. 2015. View Article : Google Scholar : PubMed/NCBI
17	Li DJ, Feng ZC, Li XR and Hu G: Involvement of methylation-associated silencing of formin 2 in colorectal carcinogenesis. World J Gastroenterol. 24:5013–5024. 2018. View Article : Google Scholar : PubMed/NCBI
18	Zhu L, Wang H, Jiang C, Li W, Zhai S, Cai X, Wang X, Liao L, Tao F, Jin D, et al: Clinically applicable 53-Gene prognostic assay predicts chemotherapy benefit in gastric cancer: A multicenter study. EBioMedicine. 61:1030232020. View Article : Google Scholar : PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Bertoli C, Skotheim JM and de Bruin RA: Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 14:518–528. 2013. View Article : Google Scholar : PubMed/NCBI
21	Zhang H, Wang Y, Wang Y, Wu D, Lin E and Xia Q: Intratumoral and intertumoral heterogeneity of HER2 immunohistochemical expression in gastric cancer. Pathol Res Pract. 216:1532292020. View Article : Google Scholar : PubMed/NCBI
22	Dai J, Peng T and Yu X: NK6 homeobox 2 regulated gastrokin-2 suppresses gastric cancer cell proliferation and invasion via Akt signaling pathway. Cell Biochem Biophys. 79:123–131. 2021. View Article : Google Scholar : PubMed/NCBI
23	Han X, Zhang HB, Li XD and Wang ZA: Long non-coding RNA X-inactive-specific transcript contributes to cisplatin resistance in gastric cancer by sponging miR-let-7b. Anticancer Drugs. 31:1018–1025. 2020. View Article : Google Scholar : PubMed/NCBI
24	Gao N, Yang F, Chen S, Wan H, Zhao X and Dong H: The role of TRPV1 ion channels in the suppression of gastric cancer development. J Exp Clin Cancer Res. 39:2062020. View Article : Google Scholar : PubMed/NCBI
25	Li Z, Gao H, Liu Y, Wu H, Li W, Xing Y, Zhang Z and Zhang X: Genetic variants in the regulation region of TLR4 reduce the gastric cancer susceptibility. Gene. 767:1451812021. View Article : Google Scholar : PubMed/NCBI
26	Jurmeister S, Baumann M, Balwierz A, Keklikoglou I, Ward A, Uhlmann S, Zhang JD, Wiemann S and Sahin Ö: MicroRNA-200c represses migration and invasion of breast cancer cells by targeting actin-regulatory proteins FHOD1 and PPM1F. Mol Cell Biol. 32:633–651. 2012. View Article : Google Scholar : PubMed/NCBI
27	Gasteier JE, Madrid R, Krautkrämer E, Schröder S, Muranyi W, Benichou S and Fackler OT: Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism. J Biol Chem. 278:38902–38912. 2003. View Article : Google Scholar : PubMed/NCBI
28	Gardberg M, Kaipio K, Lehtinen L, Mikkonen P, Heuser VD, Talvinen K, Iljin K, Kampf C, Uhlen M, Grénman R, et al: FHOD1, a formin upregulated in epithelial-mesenchymal transition, participates in cancer cell migration and invasion. PLoS One. 8:e749232013. View Article : Google Scholar : PubMed/NCBI
29	Haraguchi T, Kondo M, Uchikawa R, Kobayashi K, Hiramatsu H, Kobayashi K, Chit UW, Shimizu T and Iba H: Dynamics and plasticity of the epithelial to mesenchymal transition induced by miR-200 family inhibition. Sci Rep. 6:211172016. View Article : Google Scholar : PubMed/NCBI
30	Perdigão-Henriques R, Petrocca F, Altschuler G, Thomas MP, Le MT, Tan SM, Hide W and Lieberman J: miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene. 35:158–172. 2016. View Article : Google Scholar : PubMed/NCBI
31	Peippo M, Gardberg M, Lamminen T, Kaipio K, Carpén O and Heuser VD: FHOD1 formin is upregulated in melanomas and modifies proliferation and tumor growth. Exp Cell Res. 350:267–278. 2017. View Article : Google Scholar : PubMed/NCBI